Neuroglympse: Transforming Mental Health with Digital Therapeutics
Neuroglympse utilizes FDA-cleared digital therapeutics for chronic insomnia and generalized anxiety disorder, backed by extensive clinical research.
Neuroglympse: Advancing Digital Mental Health
FDA-Cleared for GAD
The US FDA has granted clearance to DaylightRx—a digital therapeutic now available through Neuroglympse—for the treatment of generalized anxiety disorder (GAD).
Clinical Excellence
Our solutions deliver evidence-based treatments through accessible digital platforms, enabling better access to mental healthcare.
Patient-Centered Care
Designed to meet patients where they are—at home, work, or anywhere care is needed.
SleepioRx: An FDA-Cleared Digital Treatment for Chronic Insomnia
Prescription digital therapeutic
Medically prescribed treatment solution
Cognitive Behavioral Therapy
Delivers gold-standard CBT-I treatment
First-line treatment
Recommended as the initial approach for chronic insomnia
Evidence-Based, Clinically Proven
22
Clinical Trials
Published in prestigious journals
76%
Improvement Rate
Patients with significant insomnia reduction
54%
Faster Sleep
Reduction in time to fall asleep
62%
Less Waketime
Reduction in nighttime wakefulness
Why Providers Trust SleepioRx
Instant Access
No waitlists. No need to refer out. Patients can begin evidence-based treatment right away.
Non-Drug Option
Over 75% of patients prefer non-drug treatments. SleepioRx addresses root causes, not just symptoms.
Seamless Integration
Easy, low-lift implementation enhances patient care without adding operational burden.
Real Stories, Real Impact
"SleepioRx gave me the tools to rebuild my sleep routine after years of insomnia. I finally feel rested again."
"It's science-based, interactive, and easy to follow. I wish I had found it sooner."
We're Building the Future of Mental Wellness
Superior Outcomes
Clinically validated results
FDA-Cleared Solutions
Regulated digital therapeutics
Accessible Mental Healthcare
Meeting patients where they are
Want to Bring SleepioRx or DaylightRx to Your Patients or Organization?
Healthcare Systems
Integrate digital therapeutics into your care pathways
Employers
Enhance employee wellness programs
Health Plans
Improve outcomes while reducing costs
Providers
Expand your treatment options
Important Safety Information
SleepioRx Indications for Use
SleepioRx is a prescription digital therapeutic for the treatment of chronic insomnia in adults aged 18 and over, available by order of a licensed healthcare provider. It is intended to be used as an adjunct to usual care.
DaylightRx Indications for Use
DaylightRx is FDA-cleared for the treatment of generalized anxiety disorder (GAD) in adults. It should be used under the supervision of a healthcare provider.
Additional Information
Patients should read the full Indications for Use. DOC-3652 | Effective August 2024